A New Outlook for Sigma Healthcare
Once considered overvalued, the owner of Chemist Warehouse has regained investor attention following recent share price declines. The company, now known as Sigma Healthcare (ASX:SIG), has experienced a smooth transition since its reverse merger with Chemist Warehouse. However, its shares have not been performing as well as expected, losing 9% of their value over the past six months.
Despite this, analysts remain optimistic about the company’s future. RBC Capital Markets initiated coverage of Sigma with a largely positive assessment, highlighting its market-leading position and vertically integrated scale. Operating in a defensive industry, the company offers an unbeatable domestic value proposition. Additionally, it is capital light and stands to benefit from $100 million in cost benefits from the merger.
Sigma’s expansion into New Zealand is also showing promising results, with chemists there occasionally running out of stock. RBC projects a compound annual earnings per share growth of 14.8% up to the 2028-29 year. However, the firm maintains a ‘sector perform’ call on the stock, with a $2.50 per share valuation, which is about 7% below the current stock price.
Analysts’ Perspectives
Morgans has added Sigma to its list of best share ideas, citing its defensive capabilities, best-in-class position, and offshore expansion opportunities. The firm assigns a higher price target of $3.36 per share, implying 26% upside. Citi remains neutral on the stock, with a $3.20 target price, while UBS valued Sigma at $3.35 per share. Barrenjoey has reduced its price target to $3.30 per share, noting that Sigma is a wonderful business but criticising the lack of disclosure around its international operations.
Ord Minnett has upgraded Sigma from an ‘accumulate’ to a buy, with a $3.30 target price. Despite challenges such as exposure to higher fuel costs and supply disruptions, the company continues to show resilience.
Market Performance and Future Prospects
Can Sigma surpass its peak of $3.28 achieved in mid-June last year? While the unanimous view is optimistic, investors are advised to remain cautious.
Emerging Players in the Market
Meanwhile, PathkeyAI has secured a modest but significant customer deal. The developer of AI analytics for clinical trials has signed a contract with Imunexus Therapeutics, which is developing novel immunotherapies for neuroinflammatory and autoimmune diseases. The deal is expected to contribute to Pathkey’s revenue, with $25,000 payable upon execution of the agreement. This marks an important commercial milestone for the company.
Algorae Pharmaceuticals has also made progress, with the TGA accepting its initial registration dossier for evaluation. This is a significant step in the company’s pathway to product commercialisation in the Australian market.
Leadership Changes and Collaborations
Vitura Health has appointed a new CEO, Justin James, who brings extensive experience in healthcare, regulatory, governance, and business transformation roles. His appointment follows the departure of Geoff Cockerill, who served for just over a year.
Paradigm Biopharmaceuticals has formed a collaboration with City St George’s, University of London, to investigate bone marrow OA lesions. This effort aims to support the growing body of evidence regarding the disease-modifying potential of Paradigm’s drug candidate.
Conclusion
The health sector continues to evolve, with companies like Sigma Healthcare, PathkeyAI, Algorae Pharmaceuticals, Vitura Health, and Paradigm Biopharmaceuticals making strides in their respective fields. As these companies navigate challenges and opportunities, their performance will be closely watched by investors and industry observers alike.
